Hepatocyte transplantation for metabolic disorders, experience at King's College hospital and review of literature.
Hepatocyte transplantation is emerging as a potential treatment for liver based metabolic disorders and acute liver failure. To date, clinical studies have shown that hepatocyte transplantation could be used as a "bridge" to liver transplantation in a few patients with acute liver failure and has changed the phenotype of metabolic patients in terms of reducing the severity of illness. For many years, research studies have been carried out to optimise conditions for a) hepatocyte isolation in order to obtain the highest possible number of viable hepatocytes isolated from various sources of unused donor liver tissues, and b) cryopreservation and storage of hepatocytes for immediate cell availability in emergency cases. In this review, we summarise the worldwide clinical experience in hepatocyte transplantation for liver based metabolic disorders including the experience of our centre at King's College Hospital, London (United Kingdom). We briefly comment on the possible future developments and improvements needed in this field.
Dhawan
A
A
Institute of Liver Studies, King's College London School of Medicine and King's College Hospital, London. anil.dhawan@kcl.ac.uk
Mitry
R R
RR
Hughes
R D
RD
D000293:Adolescent; D000328:Adult; D017690:Cell Transplantation / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006085:Graft Survival; D022781:Hepatocytes / Q000637:transplantation*; D006785:Hospitals, University; D006801:Humans; D017114:Liver Failure, Acute / Q000175:diagnosis / Q000628:therapy*; D016031:Liver Transplantation; D008297:Male; D008661:Metabolism, Inborn Errors / Q000175:diagnosis / Q000628:therapy*; D008875:Middle Aged; D018570:Risk Assessment; D006113:United Kingdom; D014850:Waiting Lists